Abstract
Abstract Myeloid-derived suppressor cells (MDSCs) plays an important role in controlling the immune response against cancer and in suppressing autoimmunity and allergic inflammation. However, the therapeutic effect of MDSCs on experimental mouse model of atopic dermatitis (AD) has not been reported. We investigated the therapeutic efficacy of human myeloid-derived suppressor cells expanded from cord blood (hUCB-MDSCs) in dermatophagoides farinae (Df)-induced AD-like skin lesions in NC/Nga mice and explored the mechanisms involved. The administration of hUCB-MDSCs (1×105 and 1×106 cells per mouse) significantly reduced in clinical severity scores and was associated with the reduction of histopathological changes including inflammatory cellular infiltration, epidermal hyperplasis, and hyperkeratosis. hUCB-MDSCs decreased the serum levels of IgE, Th2-mediated cytokines and chemokines. Particularly, the expression of filaggrin and involucrin in the skin lesions was recovered, whereas the expression of keratin-10 and keratin-14 decreased. These immunomodulatory effects of hUCB-MDSCs in a murine model of AD may provide helpful evidence for the clinical development of cell therapies to treat AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
